The Role of Uric Acid in Mediating Weight Change Patterns and Cardiovascular Health

Keywords

Mediating effect, Cardiovascular health, Obesity, Adult, Uric acid, Weight change

Abstract

Introduction

Obesity and weight fluctuations across adulthood are well-documented risk factors for cardiovascular diseases (CVDs), while serum uric acid has emerged as a potential metabolic intermediary influencing cardiovascular health (CVH). However, limited research has explored the life-stage-specific relationships between weight changes, uric acid levels, and CVH trajectories, particularly the mediating role of uric acid in these associations.

Material and methods

Multivariate linear regression was used to evaluate the associations between weight changes, uric acid levels, and CVH score patterns among 1,257 participants in NHANES cycles (2013–2018). Mediation analysis via bootstrap tests was conducted to investigate the role of uric acid in BMI–CVH relationships across life stages, with stratified analysis by sex.

Results

Obesity in early and middle adulthood was significantly associated with lower CVH scores in later adulthood. Weight changes exceeding 2.5 kg and stable obesity from middle to late adulthood were linked to increased cardiovascular risk. Serum uric acid levels were negatively associated with CVH scores and positively correlated with BMI and weight gain across all life stages. Uric acid mediated the relationship between BMI and CVH, with the mediating effect being most pronounced in early adulthood. Notably, this mediation effect showed gender differences, with a consistent effect across all stages in women but being significant only in late adulthood in men.

Conclusions

These findings underscore the complex interplay between weight, uric acid, and cardiovascular health. Maintaining a stable weight and effectively managing uric acid levels, with consideration of sex-specific differences, are critical strategies for improving cardiovascular outcomes across the lifespan.

The Role of Uric Acid in Mediating Weight Change Patterns and Cardiovascular Health

Feng Chen^{1,2,3}, Hao Lin⁴, Yuansi Zhang⁵, Yu Zhang^{1*}, Maoping Chu^{2,3*}, Lingling Chen^{1*}

1. Department of Child Healthcare, Wenzhou People's Hospital, Zhejiang Province, 325000, China.

- 2. Children's Heart Center, Institute of Cardiovascular Development and Translational Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Zhejiang Province, 325000, China.
- 3. Zhejiang Provincial Clinical Research Center for Pediatric Disease, Zhejiang Province, 325000, China.
- Department of Gastroenterology, Pingyang Hospital of Wenzhou Medical University, Zhejiang Province, 325000, China.
- Department of Traditional Chinese Medicine, Wenzhou Yebo Proctology Hospital, Zhejiang Province, 325000, China.
- * E-mail addresses: 25457057@qq.com(Y. Zhang), chmping@hotmail.com(M. Chu), 13626580747@163.com(L. Chen).

Feng Chen, Hao Lin, and Yuansi Zhang contributed equally as co-first authors.

Abstract

Introduction: Obesity and weight fluctuations across adulthood are well-documented risk factors for cardiovascular diseases (CVDs), while serum uric acid has emerged as a potential metabolic intermediary influencing cardiovascular health (CVH). However, limited research has explored the life-stage-specific relationships between weight changes, uric acid levels, and CVH trajectories, particularly the mediating role of uric acid in these associations.

Methods: Multivariate linear regression was used to evaluate the associations between weight changes, uric acid levels, and CVH score patterns among 1,257 participants in NHANES cycles (2013–2018). Mediation analysis via bootstrap tests was conducted to investigate the role of uric acid in BMI–CVH relationships across life stages, with stratified analysis by sex.

Results: Obesity in early and middle adulthood was significantly associated with lower CVH scores in later adulthood.

Weight changes exceeding 2.5 kg and stable obesity from middle to late adulthood were linked to increased cardiovascular risk. Serum uric acid levels were negatively associated with CVH scores and positively correlated with BMI and weight gain across all life stages. Uric acid mediated the relationship between BMI and CVH, with the mediating effect being most pronounced in early adulthood. Notably, this mediation effect showed gender differences, with a consistent effect across all stages in women but being significant only in late adulthood in men.

Conclusion: These findings underscore the complex interplay between weight, uric acid, and cardiovascular health. Maintaining a stable weight and effectively managing uric acid levels, with consideration of sex-specific differences, are critical strategies for improving cardiovascular outcomes across the lifespan.

Keywords: Cardiovascular health; Weight change; Obesity; Adult; Uric acid; Mediating effect

1. Introduction

Cardiovascular diseases (CVDs) remain the leading cause of death and a significant global health burden, particularly in the United States, where they are responsible for substantial mortality and economic costs(1). To address this growing challenge, there has been a shift in focus from managing CVD outcomes to promoting cardiovascular health (CVH) as a preventative strategy. The concept of CVH encompasses not only the absence of disease but also the optimization of health behaviors and biological factors that reduce CVD risk. Recognizing this, the American Heart Association recently updated its framework for CVH assessment by introducing the Life's Essential 8 (LE8) scoring system, which builds upon and expands the former Life's Simple 7 (LS7) system. Studies have established a strong association between LS7 scores and CVD incidence and mortality(2, 3). The LE8 system enhances this framework by incorporating additional elements critical for CVH, including diet, physical activity, nicotine exposure, body mass index (BMI), blood lipids, blood glucose, blood pressure, and sleep health(4). Notably, the inclusion of BMI as a core component highlights the pivotal role of weight management in maintaining and improving CVH.

Obesity is a well-established major risk factor for both CVD and impaired CVH. In the U.S., the prevalence of obesity among adults has reached an alarming 42.4%(5). Research consistently shows that obesity not only contributes to type 2 diabetes, certain cancers, and premature death but also significantly increases the likelihood of cardiovascular

events and mortality(6-8). In addition to its static association with cardiovascular risk, obesity also impacts CVH dynamically through weight fluctuations across different life stages. Recent studies indicate that sustained obesity throughout adulthood, weight gain from early to middle adulthood, and weight reduction from middle to late adulthood are associated with increased risks of mortality and adverse cardiovascular outcomes(9, 10). These findings underscore the need to investigate how specific patterns of weight changes at different life stages influence CVH, as such insights may inform targeted interventions for improving long-term cardiovascular outcomes.

Recent evidence suggests that weight changes across adulthood not only impact CVH directly but also may exert their effects through metabolic intermediaries, such as uric acid(11, 12). Uric acid, the end product of purine metabolism, has been identified as a significant contributor to cardiovascular risk(13). Elevated uric acid levels are associated with oxidative stress, endothelial dysfunction, and inflammation, all of which are critical pathways in the development of cardiovascular diseases(14). Additionally, obesity, a key driver of weight changes, has been closely linked to increased uric acid levels due to impaired renal clearance and heightened systemic inflammation(15, 16). Despite these established associations, limited attention has been given to the role of uric acid as a mediator in the relationship between weight changes and CVH across different life stages.

Therefore, this study investigated the impact of weight changes and weight change patterns during early, middle, and late adulthood on CVH scores. Additionally, we examined the potential mediating role of uric acid in the relationship between BMI at different life stages and CVH. By exploring how uric acid mediates this association, we aimed to elucidate the metabolic pathways linking weight dynamics to cardiovascular risk across adulthood.

2. Materials and methods

2.1. Study population

The NHANES, initiated by the Centers for Disease Control and Prevention (CDC), is a pivotal survey program designed to collect data regularly on the health and nutritional status of the U.S. population. This program employs a set of standardized and validated tools, including comprehensive health interviews, physical examinations, and laboratory tests, all of which have been previously developed and are widely recognized in the literature for their reliability and

validity(17). The data collection procedures strictly adhered to the ethical standards authorized by the Institutional Review Board of the National Center for Health Statistics (NCHS) in accordance with the revised Helsinki Declaration guidelines. Prior to any health examination, participants were provided with an informed consent form and were required to sign it.

In our study, we focused on individuals with complete records of weight and height after the age of 25 years who were 50 years or older at the time of the key survey; a total of 8,674 participants were included from three consecutive NHANES cycles between 2013 and 2018. To ensure data integrity and accuracy, we excluded individuals with missing CVH score-related information (n=7,370). Additionally, individuals lacking complete weight and height data from cardiovascular surveys at ages 25 and ten years before the baseline survey were also excluded (n=47). We subsequently excluded individuals lacking uric acid data (n=0). Ultimately, 1,257 participants were included in our final analysis after these selection criteria were applied (Figure S1).

2.2. Assessments of absolute weight change and weight change patterns

In this study, participant weight and height were measured at three different life phases: early adulthood (at 25 years of age), mid-adulthood (10 years before the baseline survey), and late adulthood (baseline survey period). These data were either collected or directly measured during physical examinations. To evaluate trends in weight fluctuations, we divided the fluctuations into five categories: a decrease exceeding 2.5 kg, a variation within 2.5 kg (serving as the reference group), an increase from 2.5 to just below 10.0 kg, an increase between 10 and just under 20.0 kg, and an increase surpassing 20.0 kg. Additionally, we calculated BMI by dividing weight (in kg) by the square of height (in meters). We determined the BMI at 25 years (BMI₂₅), 10 years prior to the baseline survey (BMI_{10prior}, average age 54.4 \pm 8.8 years), and at the baseline survey (BMI_{baseline}, average age 64.4 \pm 8.8 years) and classified the BMI into four categories: underweight (BMI value of less than 18.5), normal weight (BMI value between 18.5 and 25), overweight (BMI value between 25 and 30), and obese (BMI value of 30 or above). Moreover, we identified three periods for patterns of weight change: between age 25 and baseline, between 25 years of age and 10 years before baseline, and between 10 years before baseline and baseline. By comparing the BMI values at two distinct time points, we

characterized four distinct patterns of weight change: stable nonobesity (both BMI values less than 30.0), weight loss (first BMI value 30.0 or greater and second BMI value less than 30.0), weight gain (first BMI value less than 30.0 and second BMI value 30.0 or greater), and stable obesity (both BMI values 30.0 or greater).

2.3. Assessment of CVH scores

The CVH score, an all-encompassing metric, integrates four critical health factors—BMI, blood pressure, blood lipid levels, and blood glucose levels—with four key health behaviors—diet, physical activity, nicotine exposure, and sleep duration. The methods for calculating the CVH score for each indicator are detailed in the supplementary materials and the AHA Presidential Advisory(4). Table S1 presents the definitions and scoring criteria for each CVH component. The participants are scored on a scale from 0--100, which is based on these eight components, with scores categorized as high (80--100), moderate (50--79), or low (0--49). This scoring system provides a detailed understanding of individual CVH, where a higher score indicates better CVH, and a lower score indicates poorer CVH.

2.4. Assessment of serum uric acid

Serum samples were collected from the participants and maintained at -70°C until analysis. The samples were shipped to the Advanced Research and Diagnostic Laboratory (ARDL) at the University of Minnesota for serum uric acid (SUA) measurement. The Roche Cobas 6000 analyzer uses a two-point endpoint method to quantify SUA.

2.5. Covariates

In our study, we carefully selected covariates on the basis of prior literature and hypotheses related to CVH(18-20). This selection involved multiple factors. First, the following demographic variables were considered: age, sex (female or male), and race/ethnicity (Mexican American, non-Hispanic Black, non-Hispanic White, or other races). Second, socioeconomic status, as indicated by educational attainment (categories including less than high school, high school graduate, and college or above), and the poverty income ratio (PIR), divided into two levels (<1.3, \geq 1.3), were considered. Additionally. marital considered and categorized married/cohabiting, status was as divorced/widowed/separated, or single. Finally, we included alcohol consumption status and divided patients into two groups on the basis of their annual drinking amount (<12 drinks/year, ≥12 drinks/year). These variables were collected primarily through direct interviews and the assessment of biomarkers.

2.6. Statistical analyses

For the descriptive analysis in this study, continuous variables are presented as the means \pm standard deviations or medians (interquartile ranges [IQRs]). Independent sample t tests or nonparametric tests were used to examine differences between groups. Categorical variables are presented as counts (n) and percentages (%), and chi-square tests were used to assess group differences. Multivariate linear regression models were used to evaluate the relationships among weight change patterns, absolute weight changes, uric acid levels, and CVH scores by calculating effect sizes (β) and 95% confidence intervals (CIs). Two models were designed to adjust for potential confounders: Model 1 was used as a crude model, and Model 2 was further adjusted for age, sex, race, education level, income, marital status, and drinking habits. Additionally, restricted cubic spline (RCS) functions were used to determine the dose–response relationships between absolute weight changes and CVH scores. The bootstrap method was applied to assess whether uric acid serves as a mediator between BMI across three distinct life stages and CVH and to quantify the strength and statistical significance of this mediating effect. Finally, a series of sensitivity analyses were conducted to ensure the robustness of the results, including (1) adding cardiovascular disease history as a covariate, (2) examining sex differences in the mediating effect, and (3) exploring age-specific differences in the mediating role of uric acid.

All analyses were performed via R Statistical Software (version 4.3.1, http://www.R-project.org, The R Foundation) and the Free Statistical analysis platform (version 1.9, Beijing, China). A bidirectional test was employed, and a finding was deemed to be statistically significant if the P value was less than 0.05.

3. Results

3.1. Demographic characteristics of the participants

Table 1 presents the baseline characteristics of the participants, stratified by CVH score categories. Compared with those with lower CVH scores, individuals with higher CVH scores tended to be younger, more likely to be Non-Hispanic White, have higher incomes, and have higher education levels. Additionally, participants with higher CVH scores were more likely to be married or living with a partner, consume less alcohol, have a lower BMI across three different life

phases, experience smaller weight fluctuations, and have lower uric acid levels.

3.2. Associations between absolute weight changes and weight change patterns and CVH scores

Table 2 shows a linear negative correlation between the absolute weight change and the CVH score across the three different periods. Notably, compared with those in the group with a weight change of <2.5 kg, the loss of 2.5 kg or gain of more than 10 kg from age 25 to baseline had significantly negative correlations with baseline CVH scores (Figure 1). Importantly, between 25 and 10 years before baseline, a weight gain of more than 10 kg was significantly negatively correlated with the current CVH score. Conversely, from 10 years before baseline to baseline, any weight change (\geq 2.5 kg) correlated more significantly with the baseline CVH score (loss \geq 2.5: β = -2.97, 95% CI=-4.71~-1.24; gain 2.5-< 10.0: β =-7.96, 95% CI=-10.24~-5.68; gain \geq 20.0: β =-11.09, 95% CI=-13.89~-8.29).

Table S2 shows that obesity at age 25 and overweight/obese status 10 years before baseline were negatively correlated with baseline CVH scores (obesity at age 25: β = -4.71, 95% CI: -7.39~-2.03; overweight 10 years prior: β = -2.22, 95% CI: -3.81~-0.63; obesity: β = -6.56, 95% CI: -8.22~-4.9).

Table S3 presents the relationships between weight change patterns over the three periods and the CVH scores. From 25 years of age to baseline, when the stable nonobesity group was used as a reference, the CVH scores of the other three groups decreased, whereas the weight gain and stable obesity groups significantly increased (β = -9.13, 95% CI= -10.47~-7.79; β = -8.7, 95% CI= -11.57~-5.82, respectively). Similar results were observed in the other two periods, although the risk in the weight loss group was less pronounced. Moreover, we found that during the period from 10 years before baseline to baseline, the stable obesity group faced the greatest risk of poor CVH, with β = -11.86 and 95% CI= -17.8~-5.91.

3.3. Associations between uric acid and CVH scores

Table 3 shows the associations between serum uric acid levels and CVH scores. According to the univariate model, a continuous increase in uric acid by 1 mg/dL was significantly associated with a decrease in the CVH score (β = -1.15, 95% CI: -1.62 to -0.67, P < 0.001). After adjusting for potential confounders, including age, sex, race, education, income, marital status, and drinking habits, the multivariate model revealed a stronger negative association (β = -1.24, 95% CI: -1.73--0.74, P < 0.001).

When uric acid levels were analyzed by quartiles, the associations with CVH scores became more pronounced in higher quartiles. Compared with Quartile 1 (reference group), Quartile 3 (β = -3.36, 95% CI: -5.3 to -1.42, P = 0.001) and Quartile 4 (β = -4.2, 95% CI: -6.14 to -2.27, P < 0.001) showed significant negative correlations with CVH scores in the multivariate model. However, Quartile 2 showed no significant association (β = 0.32, 95% CI: -1.55 to 2.2, P = 0.736).

3.4. Associations between absolute weight changes and weight change patterns and uric acid

Table S4 shows a positive association between absolute weight changes and uric acid levels across all three life periods. From age 25 to baseline, for every 1 kg increase in weight, uric acid levels increased by 0.02 mg/dL (β = 0.02, 95% CI: 0.01–0.02, P < 0.001). Compared with those with weight changes <2.5 kg, participants who gained more than 20 kg during this period presented the greatest increase in uric acid levels (β = 0.79, 95% CI: 0.53–1.05, P < 0.001). Similar trends were observed from age 25 to 10 years before baseline and from 10 years before baseline to baseline, with larger weight gains correlating with greater increases in uric acid levels. Notably, weight loss was not significantly associated with uric acid levels in most periods.

Table S5 illustrates the associations between BMI and uric acid levels at three different life stages: 25 years, 10 years before baseline, and baseline. At age 25, obesity was associated with a significant increase in uric acid levels compared with normal weight ($\beta = 0.46$, 95% CI: 0.16–0.76, P = 0.003). Overweight also showed a positive association ($\beta = 0.23$, 95% CI: 0.05–0.41, P = 0.014). Ten years before baseline, both overweight ($\beta = 0.49$, 95% CI: 0.31–0.67, P < 0.001) and obesity ($\beta = 0.55$, 95% CI: 0.36–0.73, P < 0.001) demonstrated stronger associations with higher uric acid levels. At baseline, the associations remained significant, with overweight ($\beta = 0.47$, 95% CI: 0.28–0.65, P < 0.001) and obesity ($\beta = 0.81$, 95% CI: 0.62–0.99, P < 0.001) linked to elevated uric acid levels.

Table S6 shows that weight change patterns over the three life periods significantly affected uric acid levels. Using the stable nonobese group as a reference, the stable obese group consistently presented the highest uric acid levels across all periods. From age 25 to baseline, stable obesity was associated with an increase in uric acid levels ($\beta = 0.69, 95\%$ CI: 0.35-1.03, P < 0.001). Similarly, weight gain patterns also showed significant positive associations with uric acid levels, with the effect size varying by period. Weight loss patterns were less strongly associated with uric acid, and the associations were not statistically significant in most cases.

3.5. Mediation analysis

To explore the potential mediating role of uric acid between BMI at different life stages and CVH, we conducted a mediation analysis. Figure 2 shows that uric acid significantly mediated the relationship between BMI and CVH.

At baseline (late adulthood), the indirect effect of uric acid was $\beta 1 * \beta 2 = -0.0245$, 95% CI = -0.0492 to -0.0027, P = 0.024, with a mediation ratio of 3%. Ten years prior (mid-adulthood), the indirect effect of uric acid was $\beta 1 * \beta 2 = -0.0318$, 95% CI = -0.0549 to -0.0134, P < 0.001, with a mediation ratio of 6%. At age 25 (early adulthood), the indirect effect of uric acid was $\beta 1 * \beta 2 = -0.0122$, 95% CI = -0.0461 to -0.0017, P = 0.01, with a mediation ratio of 19%. These findings indicate that uric acid plays a mediating role in the association between BMI and CVH during early and late adulthood, with a notably greater mediation ratio in early adulthood.

3.6. Sensitivity analysis

When CVD history was included as a covariate in the mediation analysis, the results remained robust (Figure S2). Gender-specific differences were observed: in men, uric acid mediated only the relationship between BMI in late adulthood and CVH, whereas in women, uric acid consistently mediated the relationship across all life stages (Figure S3-4). Additionally, in the older age group (\geq 65 years), the mediating role of uric acid remained significant, whereas in the middle-aged group (<65 years), this mediating effect was no longer observed (Figure S5-6).

4. Discussion

This study highlights the significant relationships between weight changes, BMI, uric acid levels, and CVH across adulthood. Absolute weight changes and patterns of weight gain or stable obesity were consistently associated with poorer CVH scores and elevated uric acid levels. Uric acid emerged as a mediator between BMI and CVH, with a stronger mediating effect in early adulthood. Gender- and age-specific differences were evident, with uric acid playing a more pronounced mediating role in women and older adults (\geq 65 years). Importantly, this study is the first to explore

the mediating role of uric acid in the relationship between weight changes and cardiovascular health across different life stages, which represents a novel contribution to the literature. These findings emphasize the interconnected roles of weight management, metabolic factors, and demographic characteristics in shaping cardiovascular outcomes throughout life.

Our analysis revealed the substantial impact of obesity on CVH. Shihab et al. demonstrated that obesity in young adults is closely linked to the development of hypertension in adulthood, with lifetime weight gain increasing the risk of this condition(21). Additionally, Kjøllesdal et al. reported that obesity during both early and middle adulthood is associated with an increased mortality rate from CVD(22). These findings are consistent with the results of our study. The inflammation, metabolic disorders, and endothelial dysfunction caused by obesity are likely key mechanisms contributing to the worsening of CVH(23, 24). Another key finding is the close correlation between the absolute changes in participants' weight throughout adulthood and their patterns of weight change with CVH scores. A randomized controlled trial revealed that weight fluctuations among participants with coronary artery disease were associated with higher mortality rates and a greater incidence of cardiovascular events(9). Mengyi Liu et al. reported that weight change patterns from nonobese to obese, obese to nonobese, and persistent obesity from youth to middle age are associated with an increased risk of CVD(25). All these studies support our conclusions. Mechanistic studies have shown that severe weight fluctuations can lead to metabolic disorders, increase the cardiac burden, and may cause instability in blood pressure and blood sugar levels, thereby affecting the cardiovascular system(26-28). These findings are consistent with our conclusions. Weight management clearly extends beyond obesity alone, encompassing absolute changes in weight and patterns of weight change across the adult lifespan.

Our research indicated that weight fluctuations during middle to late adulthood are associated with greater cardiovascular risk than fluctuations in weight during early to middle adulthood. This difference may be attributed to the physiological, chronic disease, and lifestyle specifics of older adults. With advancing age, a reduced metabolic rate and diminished adaptability of the cardiovascular system make the impact of weight fluctuations more pronounced on CVH(29, 30). Additionally, older adults often have more chronic health issues, such as hypertension, high cholesterol,

and diabetes, which may render the cardiovascular system more sensitive to weight fluctuations. Lifestyle changes, such as reduced physical activity and alterations in dietary habits, could also exacerbate this impact. Notably, weight fluctuations in older adults might involve changes in muscle mass rather than just fat(31, 32), which could have different effects on CVH(33, 34). These findings underscore the importance of weight management and health maintenance in older age groups.

This study revealed a significant negative correlation between serum uric acid levels and CVH scores, with this association being more pronounced among participants with high uric acid levels. This finding aligns with previous studies demonstrating that hyperuricemia promotes the development and progression of cardiovascular diseases by regulating molecular signals, such as inflammation, oxidative stress, insulin resistance/diabetes, endoplasmic reticulum stress, and endothelial dysfunction(35). Elevated uric acid levels can impact CVH through several mechanisms. First, uric acid promotes oxidative stress, leading to the production of reactive oxygen species (ROS) that impair endothelial function. Uric acid also activates the renin–angiotensin–aldosterone system (RAAS), causing vasoconstriction and elevated blood pressure, further harming CVH(14). Second, uric acid induces inflammatory responses by increasing the release of proinflammatory cytokines, which accelerates the development of atherosclerosis(36).

This study also revealed a positive correlation between body mass index (BMI) and serum uric acid levels across all life stages, with the association being most pronounced among individuals with obesity. This finding is consistent with recent research demonstrating a close relationship between obesity and hyperuricemia(37). Obesity may affect uric acid metabolism through several mechanisms. First, obesity is often accompanied by insulin resistance, which increases renal tubular reabsorption of uric acid and reduces its clearance(15). Second, chronic low-grade inflammation associated with obesity can promote uric acid production and accumulation(16). Additionally, this study revealed that absolute weight gain, particularly weight gain exceeding 10–20 kilograms, was significantly associated with elevated uric acid levels. This finding suggests that sustained weight gain has a substantial effect on uric acid metabolism, potentially exacerbating cardiovascular risks through the mechanisms mentioned above(38).

Through mediation analysis, this study revealed that uric acid partially mediated the relationship between BMI and

CVH across different life stages, with the mediating effect being most prominent in early adulthood. This finding is consistent with recent research indicating a strong association between early adulthood BMI and the risk of hyperuricemia later in life(39). Uric acid may act as a mediator through multiple mechanisms. First, obesity leads to increased uric acid production and reduced excretion, resulting in hyperuricemia. Elevated uric acid levels promote oxidative stress and inflammation, impairing endothelial function and ultimately worsening CVH. Additionally, metabolic abnormalities associated with obesity, such as insulin resistance and lipid metabolism disorders, may further exacerbate cardiovascular risks by increasing uric acid levels.

The observed sex differences in the mediating role of uric acid between BMI and CVH may be attributed to the regulatory effects of sex hormones on uric acid metabolism and endothelial function. In women, estrogen provides protective effects by promoting nitric oxide (NO) production, reducing oxidative stress, and regulating uric acid excretion (e.g., upregulating the uric acid transporter ABCG2). These protective effects during reproductive age may have long-term benefits for CVH, with the cumulative advantages persisting even after menopause despite declining estrogen levels. Consequently, women exhibit consistent uric acid-mediated effects across all life stages. In contrast, in men, androgens may limit NO production, increase oxidative stress, and impair uric acid clearance, exerting detrimental effects on endothelial function. However, in early adulthood, men may not yet have accumulated a sufficient metabolic burden for uric acid to significantly impact CVH. With aging and the worsening of metabolic disorders (e.g., obesity and insulin resistance), uric acid levels increase, and its detrimental effects on endothelial function become more pronounced, explaining the significant mediating effect of uric acid, which is primarily observed in late adulthood in men(40).

Strengths and limitations

This retrospective study, which is based on the NHANES database, has several notable strengths and limitations. A primary strength is the comprehensive nature of the NHANES, which includes detailed biomarker data, such as serum uric acid levels, enabling a robust analysis of its mediating role in the relationship between BMI and CVH across different life stages, a perspective not extensively explored in prior research. The dataset's large, nationally representative sample ensures statistical power and generalizability within the U.S. population. Additionally, the availability of diverse covariates allows for extensive adjustments, whereas age-stratified analysis provides valuable insights into life-stage-specific patterns of weight changes and their cardiovascular implications. However, several limitations exist. The cross-sectional nature of certain biomarker data, including uric acid, limits causal inference, and the reliance on self-reported weight at earlier life stages introduces potential recall bias. Furthermore, the absence of genetic information and unaccounted behavioral factors, such as stress or physical activity, may contribute to residual confounding. Finally, while the findings are relevant to the U.S. population, their generalizability to other regions may be limited due to cultural and healthcare differences.

5. Conclusions

In conclusion, this study highlights the significant associations between weight changes, BMI, serum uric acid levels, and CVH across different adult life stages. Uric acid has emerged as a crucial mediator in the relationship between BMI and CVH, with notable sex- and age-specific differences. These findings emphasize the importance of weight management throughout adulthood and the need to address metabolic factors, such as uric acid, to improve cardiovascular outcomes. Clinically, these results suggest that serum uric acid could serve as an important marker for cardiovascular risk in patients with obesity, especially those with significant weight fluctuations. Monitoring uric acid levels alongside BMI could enhance the prediction and early diagnosis of cardiovascular risk, leading to more targeted and personalized management strategies. In addition, managing weight changes and controlling uric acid levels could be vital components in improving cardiovascular health for patients at high risk of CVD. Future research should explore targeted interventions that consider these sex- and age-specific patterns, as well as the interplay between metabolic and behavioral factors, to optimize CVH across diverse populations.

Conflict of interests The authors declare no competing interests.

Ethics Statement The National Center for Health Statistics (NCHS) Ethics Review Board and the Centers for Disease Control and Prevention (CDC) both gave their approval to the survey protocol(Protocol #2011-17, Continuation of Protocol #2011-17), and this study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). All

participants gave written informed consent.

Consent for publication All individuals provided written informed consent before participating in the study.

Author Contribution Feng Chen, Maoping Chu and Lingling Chen designed the study; Feng Chen, Hao Lin and Yuansi Zhang wrote the manuscript. Feng Chen, Yuansi Zhang, and Yu Zhang collected, analyzed and interpreted the data. Yu Zhang, Maoping Chu and Lingling Chen critically reviewed, edited and approved the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Funding No funding was received for conducting this study.

Data Availability The study's original contributions are available to the public. You can find this data at the NHANES

(https://www.cdc. gov/nchs/nhanes).

References

1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528.

2. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. Jama. 2012;307(12):1273-83.

3. Ford ES, Greenlund KJ, Hong Y. Ideal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United States. Circulation. 2012;125(8):987-95.

4. Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation. 2022;146(5):e18-e43.

5. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS data brief. 2020(360):1-8.

6. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384(9945):755-65.

7. Hruby A, Manson JE, Qi L, Malik VS, Rimm EB, Sun Q, et al. Determinants and Consequences of Obesity. American journal of public health. 2016;106(9):1656-62.

8. Bangalore S, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. The New England journal of medicine. 2017;377(1):95-6.

9. Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. The New England journal of medicine. 2017;376(14):1332-40.

10. Okada C, Kubota Y, Eshak ES, Cui R, Tamakoshi A, Iso H. Weight Change and Mortality from Cardiovascular Diseases: The Japan Collaborative Cohort Study. Journal of atherosclerosis and thrombosis. 2021;28(1):25-33.

11. Reschke LD, Miller ER, 3rd, Fadrowski JJ, Loeffler LF, Holmes KW, Appel LJ, et al. Elevated uric acid and obesity-related cardiovascular disease risk factors among hypertensive youth. Pediatric nephrology (Berlin, Germany). 2015;30(12):2169-76.

12. Skak-Nielsen H, Torp-Pedersen C, Finer N, Caterson ID, Van Gaal L, James WP, et al. Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PloS one. 2013;8(3):e59121.

13. Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey. Atherosclerosis. 2019;284:44-9.

14. Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA. Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment. International journal of molecular sciences. 2022;23(6).

15. Yu W, Xie D, Yamamoto T, Koyama H, Cheng J. Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond. Reviews in endocrine & metabolic disorders. 2023;24(2):327-43.

16. Foster C, Smith L, Alemzadeh R. Excess serum uric acid is associated with metabolic syndrome in obese adolescent patients. Journal of diabetes and metabolic disorders. 2020;19(1):535-43.

17. Sun X, Du T. Trends in weight change patterns across life course among US adults, 1988-2018: population-based study. BMC public health. 2023;23(1):2168.

18. Chen F, Zhang Y, Chen S. The inverted U-shaped relationship between weight loss percentage and cardiovascular health scores. Eating and weight disorders : EWD. 2023;28(1):87.

19. Chen F, Yang E, Zhang Y, Zhang Y. Association between serum vitamin D concentrations and Life's Essential 8 score in American adolescents. Arch Med Sci. 2025;21(1):42-50.

20. Chen F, Lin H, Zhang Y, Zhang Y, Yang E. The mediating effect of depression on the association between lung disease and cardiovascular health. Arch Med Sci. 2024;20(3):1029-33.

21. Shihab HM, Meoni LA, Chu AY, Wang NY, Ford DE, Liang KY, et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012;126(25):2983-9.

22. Kjøllesdal MKR, Ariansen I, Næss Ø E. Early adulthood weight, subsequent midlife weight change and risk of cardiovascular disease mortality: an analysis of Norwegian cardiovascular surveys. International journal of obesity (2005). 2020;44(2):399-408.

23. Iantorno M, Campia U, Di Daniele N, Nistico S, Forleo GB, Cardillo C, et al. Obesity, inflammation and endothelial dysfunction. Journal of biological regulators and homeostatic agents. 2014;28(2):169-76.

24. Campia U, Tesauro M, Cardillo C. Human obesity and endothelium-dependent responsiveness. British journal of pharmacology. 2012;165(3):561-73.

25. Liu M, Zhang Z, Zhou C, He P, Zhang Y, Li H, et al. Relationship of Weight Change Patterns From Young to Middle Adulthood With Incident Cardiovascular Diseases. The Journal of clinical endocrinology and metabolism. 2021;106(2):e812-e23.

26. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. Journal of the American College of Cardiology. 2006;47(6):1093-100.

27. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM cardiovascular disease. 2016;5:2048004016633371.

28. Grundy SM. What is the contribution of obesity to the metabolic syndrome? Endocrinology and metabolism clinics of North America. 2004;33(2):267-82, table of contents.

29. Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N, et al. Hypertension in older adults: Assessment, management, and challenges. Clinical cardiology. 2020;43(2):99-107.

30. Haywood CJ, Prendergast LA, Lim R, Lappas M, Lim WK, Proietto J. Obesity in older adults: Effect of degree of weight loss on cardiovascular markers and medications. Clinical obesity. 2019;9(4):e12316.

31. Evans K, Abdelhafiz D, Abdelhafiz AH. Sarcopenic obesity as a determinant of cardiovascular disease risk in older people: a systematic review. Postgraduate medicine. 2021;133(8):831-42.

32. Atkins JL, Wannamathee SG. Sarcopenic obesity in ageing: cardiovascular outcomes and mortality. The British journal of nutrition. 2020;124(10):1102-13.

33. Ma J, Hwang SJ, McMahon GM, Curhan GC, McLean RR, Murabito JM, et al. Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity. Obesity (Silver Spring, Md). 2016;24(2):526-34.

34. Hong SH, Choi KM. Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences. International journal of molecular sciences. 2020;21(2).

35. Yu W, Cheng JD. Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective. Frontiers in pharmacology. 2020;11:582680.

36. Deng Y, Liu F, Yang X, Xia Y. The Key Role of Uric Acid in Oxidative Stress, Inflammation, Fibrosis, Apoptosis, and Immunity in the Pathogenesis of Atrial Fibrillation. Frontiers in cardiovascular medicine. 2021;8:641136.

37. Deng F, Wang Q, Wen X, Xu X, Jia L, He H, et al. Association between Body Mass Index and Serum Uric Acid: mediation analysis involving liver enzymes indicators. BMC public health. 2024;24(1):3007.

38. Corso LML, Wing RR, Tate DF, Espeland MA, Blanchard BE, McCaffery JM. Uric acid as a predictor of weight gain and cardiometabolic health in the Study of Novel Approaches to Weight Gain Prevention (SNAP) study. International journal of obesity (2005). 2022;46(8):1556-9.

39. Qian Y, Kong YW, Wan NJ, Yan YK. Associations between body mass index in different childhood age periods and hyperuricemia in young adulthood: the China Health and Nutrition Survey cohort study. World journal of pediatrics : WJP. 2022;18(10):680-6.

40. Ciarambino T, Crispino P, Giordano M. Hyperuricemia and Endothelial Function: Is It a Simple Association or Do Gender Differences Play a Role in This Binomial? Biomedicines. 2022;10(12).

	Total (n =	Low CVH	Moderate	High CVH	P value
Characteristic	1257)	(n = 119)	CVH (n =	(n = 157)	
			981)		
Sex ^a					0.502
Male	780 (62.1)	71 (59.7)	617 (62.9)	92 (58.6)	
Female	477 (37.9)	48 (40.3)	364 (37.1)	65 (41.4)	
Age, years ^a	64.4 ± 8.8	66.8 ± 9.8	64.4 ± 8.7	61.8 ± 7.2	< 0.001
Race ^a					0.004
Mexican American	117 (9.3)	13 (10.9)	96 (9.8)	8 (5.1)	
Non-Hispanic White	596 (47.4)	42 (35.3)	464 (47.3)	90 (57.3)	
Non-Hispanic Black	295 (23.5)	40 (33.6)	229 (23.3)	26 (16.6)	
Other race	249 (19.8)	24 (20.2)	192 (19.6)	33 (21)	
Family poverty-income ratio ^a					< 0.001
<1.3	287 (22.8)	41 (34.5)	228 (23.2)	18 (11.5)	
≥1.3	970 (77.2)	78 (65.5)	753 (76.8)	139 (88.5)	

Table 1 Baseline characteristics of participants classified by CVH category

Educational level^a

Below high school	191 (15.2)	27 (22.7)	149 (15.2)	15 (9.6)	
High-school graduate	292 (23.2)	34 (28.6)	236 (24.1)	22 (14)	
College or above	774 (61.6)	58 (48.7)	596 (60.8)	120 (76.4)	
MS ^a					0.022
Married/living with partner	747 (59.4)	62 (52.1)	576 (58.7)	109 (69.4)	
Widowed/divorced/separated	425 (33.8)	44 (37)	340 (34.7)	41 (26.1)	
Never married	85 (6.8)	13 (10.9)	65 (6.6)	7 (4.5)	
Drinking status ^a					0.797
No	856 (68.1)	78 (65.5)	672 (68.5)	106 (67.5)	
Yes	401 (31.9)	41 (34.5)	309 (31.5)	51 (32.5)	
Body mass index, kg/m ^{2 a}					
At age 25 years	23.7 ± 7.0	24.2 ± 4.0	23.9 ± 7.7	22.3 ± 3.3	0.023
At 10 years before baseline	28.5 ± 6.2	31.5 ± 8.0	28.5 ± 5.9	26.0 ± 5.4	< 0.001
At baseline	29.0 ± 5.9	33.2 ± 7.6	29.2 ± 5.6	25.1 ± 3.6	< 0.001
Absolute weight change, kg ^b					
	12.4 (3.9,	23.6 (10.0,	13.1 (4.9,	4.7 (-0.5,	< 0.001
From age 25 years to baseline	21.9)	34.0)	21.8)	11.4)	< 0.001
From age 25 years to 10 years before	1.1 (-4.9,	5.5 (-5.5,	1.4 (-4.9,	-0.5 (-4.8,	< 0.001
baseline	8.1)	16.2)	8.4)	3.8)	< 0.001
	9.1 (2.3,	13.6 (6.8,	9.1 (2.3,	4.5 (0.9,	. 0. 001
From 10 years before baseline to baseline	18.1)	26.8)	18.1)	12.7)	< 0.001
depression score ^a	5.7 ± 1.4	5.9 ± 1.4	5.7 ± 1.4	5.2 ± 1.4	< 0.001

Univariate Model Multivariate Model Variable n β (95% CI) P value β (95% CI) P value From age 25 years to baseline Continuous, per 1 kg 1257 -0.24 (-0.28~-0.2) < 0.001 $-0.24(-0.28 \sim -0.2)$ < 0.001 Categories of Absolute Weight Change, kg $Loss \ge 2.5$ 155 -3.58 (-6.27~-0.9) 0.009 -2.7 (-5.29~-0.1) 0.042 Change < 2.5(ref)127 0(Ref)0(Ref)Gain 2.5-< 10.0 260 -1.39 (-3.81~1.04) 0.263 -1.61 (-3.96~0.74) 0.179 Gain 10-< 20.0 346 -4.33 (-6.65~-2) < 0.001 -4.53 (-6.79~-2.28) < 0.001 $Gain \ge 20.0$ 369 -11.6 (-13.91~-9.3) < 0.001 -11.27 (-13.53~-9) < 0.001 From age 25 years to 10 years before baseline Continuous, per 1 kg -0.16 (-0.21~-0.11) < 0.001 -0.17 (-0.22~-0.13) <0.001 1257 Categories of Absolute Weight Change, kg

Table 2 Association between absolute weight change and CVH scores.

^a CVH cardiovascular health.

^a Continuous variables are presented as mean \pm SD; categorical variables are presented as N(%).

^b Those characteristics were presented as median (IQR).

$Loss \ge 2.5$	78	0.78 (-2.27~3.83)	0.616	-0.09 (-3.02~2.83)	0.95
Change < 2.5(ref)	252	0(Ref)		0(Ref)	
Gain 2.5-< 10.0	332	-0.44 (-2.4~1.53)	0.662	-1.54 (-3.44~0.36)	0.111
Gain 10-< 20.0	316	-2.2 (-4.19~-0.22)	0.03	-3.54 (-5.47~-1.61)	< 0.001
$Gain \ge 20.0$	279	-5.74 (-7.79~-3.7)	< 0.001	-6.78 (-8.75~-4.8)	< 0.001
From 10 years before					
baseline to baseline					
Continuous, per 1 kg	1257	-0.14 (-0.19~-0.09)	< 0.001	-0.13 (-0.17~-0.08)	< 0.001
Categories of Absolute					
Weight Change, kg					
$L_{\text{oss}} > 25$	124	-3 73 (-5 5~-1 96)	< 0.001	-2.97 (-4.71~-1.24)	0.001
$1088 \le 2.5$	424	5.75 (5.5 1.90)			
Change < 2.5 (ref)	277	0(Ref)		0(Ref)	
Loss ≥ 2.5 Change < 2.5(ref) Gain 2.5-< 10.0	424 277 309	0(Ref) -2.99 (-4.89~-1.1)	0.002	0(Ref) -2.5 (-4.37~-0.63)	0.009
Change < 2.5(ref) Gain 2.5-< 10.0	424 277 309	0(Ref) -2.99 (-4.89~-1.1)	0.002	0(Ref) -2.5 (-4.37~-0.63) -7.96 (-10.24~-	0.009
Loss ≥ 2.5 Change < 2.5(ref) Gain 2.5-< 10.0 Gain 10-< 20.0	424277309159	0(Ref) -2.99 (-4.89~-1.1) -9.08 (-11.36~-6.8)	0.002 <0.001	0(Ref) -2.5 (-4.37~-0.63) -7.96 (-10.24~- 5.68)	0.009 <0.001
Loss ≥ 2.5 Change < 2.5(ref) Gain 2.5-< 10.0 Gain 10-< 20.0	424277309159	0(Ref) -2.99 (-4.89~-1.1) -9.08 (-11.36~-6.8) -12.82 (-15.63~-	0.002 <0.001	0(Ref) -2.5 (-4.37~-0.63) -7.96 (-10.24~- 5.68) -11.09 (-13.89~-	0.009 <0.001
Loss ≥ 2.5 Change < 2.5(ref) Gain 2.5-< 10.0 Gain 10-< 20.0 Gain ≥ 20.0	 424 277 309 159 88 	0(Ref) -2.99 (-4.89~-1.1) -9.08 (-11.36~-6.8) -12.82 (-15.63~- 10.02)	0.002 <0.001 <0.001	0(Ref) -2.5 (-4.37~-0.63) -7.96 (-10.24~- 5.68) -11.09 (-13.89~- 8.29)	0.009 <0.001 <0.001

Table S1 Life's Essential 8 scoring rules

Domain	CVH metric	Method of measurement	Quantification of CVH metric	
Health	Diet	Dietary intake data were	Points:	HEI-2015 score:

^b CVH: cardiovascular health; Model 1 was a crude model; Model 2 was adjusted for age, sex, race, family PIR, educational level, marital status,

b

behaviors		collected from NHANES	100	≥95th percentiles
		participants through up to	80	75th-94th percentiles
		two 24-hour dietary	50	50th-74th percentiles
		recalls, in person during	25	25th-49th percentiles
		the first recall and by	0	1st-24th percentiles
		telephone during the		
		second recall 3-10 days		
		later. Applying HEI-2015		
		to Evaluate Dietary		
		Quality(Table S1).		
		Self-reported minutes of moderate or vigorous PA per week	Points:	Minutes:
			100	≥150
			90	120–149
	Physical		80	90–119
	activity		60	60–89
			40	30–59
			20	1–29
			0	0
			Points:	Smoking status:
			100	Never smoker
	Nicotine	Self-reported smoking	75 For	mer smoker, quit≥5 y
	exposure	status	50 F	Former smoker, 1–< 5 y
			25 Former smoker, q	uit <1 y, or currently using inhaled
			NDS	

			0	Current smoker
			Subtract 20 points (unle	ess score is 0) for living with active
			indoor smoker in home	
			Points:	Level (hours)
			100	7–<9
		a 10	90	9–<10
	Sleep health	Self-reported average	70	6-<7
		nours of sleep per night	40	$5 - < 6 \text{ or } \ge 10$
			20	4-<5
			0	<4
	BMI	Body weight (kilograms)	Points:	BMI (kg/m ²)
		(meters squared), and then compare the BMI with the specific values of the same age and sex in the reference table.	100	<25
			70	25.0–29.9
			30	30.0–34.9
			15	35.0–39.9
			0	≥40.0
Health factors			Points: N	on–HDL cholesterol (mg/dL)
			100	<130
		Plasma total and HDL	60	130–159
	Blood lipids	cholesterol with	40	160–189
		calculation of non–HDL	20	190–219
		cholesterol	0	≥220
			If drug-treated level, sul	btract 20 points (unless score is 0)

			Points:	Level:
			100	No history of T2D and HbA1c <5.7
		Measured fasting blood	60	No T2D and HbA1c 5.7–6.4
	Blood	glucose, HbA1c, and asked	40	T2D with HbA1c <7.0
	glucose	participants about their	30	T2D with HbA1c 7.0–7.9
		history of diabetes.	20	T2D with HbA1c 8.0–8.9
			10	T2D with Hb A1c 9.0–9.9
			0	T2D with HbA1c ≥ 10.0
			Points:	Systolic and diastolic BPs (mmHg)
			100	<120/<80
			75	120–129/<80
	Blood	Appropriately measured	50	130–139 or 80–89
	pressure	systolic and diastolic BPs	25	140–159 or 90–99
			0	≥160 or ≥100
			If drug-treated	level, subtract 20 points (unless score is 0)
c				

с

 Table S2 Association between body mass index at age 25 years and at 10 years before the baseline and

 CVH scores

		Univariate	Model	Multivariate Model	
Variable	n	β (95% CI) <i>P</i> value		β (95% CI)	<i>P</i> value
At age 25 years					
Continuous, per 1					0.10
kg/m ²	1257	-0.08 (-0.18~0.01)	0.087	-0.06 (-0.16~0.03)	0.18
BMI Categories					
Normal weight	828	0(Ref)		0(Ref)	
Underweight	71	0.35 (-2.58~3.29)	0.813	0.31 (-2.54~3.15)	0.833
Overweight	277	-1.41 (-3.06~0.24)	0.094	-0.88 (-2.52~0.76)	0.295
Obesity	81	-5.8 (-8.57~-3.04)	< 0.001	-4.71 (-7.39~-2.03)	0.001
At 10 years before					
baseline					
Continuous, per 1	1077		0.007		0.10
kg/m ²	1257	-0.08 (-0.18~0.01)	0.087	-0.06 (-0.16~0.03)	0.18
BMI Categories					
Normal weight	360	0(Ref)		0(Ref)	

Overweight	480	-1.56 (-3.18~0.06)	0.059	-2.22 (-3.81~-0.63)	0.006
Obesity	402	-6.46 (-8.15~-4.77)	<0.001	-6.56 (-8.22~-4.9)	< 0.001

d

Table S3 Association between weight change patterns and CVH scores

	Stable		Weight gain, β	Stable obese, β
	non-obese	(95% CI)	(95% CI)	(95% CI)
From age 25 years to				
baseline				
	0/ D - O	-6.61 (-11.52~-	-9.45 (-10.82~-	-9.43 (-12.4~-
Model I	0(Ref)	1.7)*	8.08)*	6.45)*
M-4-10		-5.12 (-9.88~-	-9.13 (-10.47~-	-8.7 (-11.57~-
Model 2	0(Kei)	0.35)*	7.79)*	5.82)*
From age 25 years to 10				
years before baseline				
Model 1	0(D of)	-5.98 (-	-5.46 (-6.97~-	-7.2 (-10.1~-
Model I	0(Ref)	13.05~1.1)	3.95)*	4.3)*

^d CVH: cardiovascular health; Model 1 was a crude model; Model 2 was adjusted for age, sex, race, family PIR, educational level, marital status, drinking status.

Wodel 2	U(KCI)	11.23~0.63)	1.6)*	5.91)*
M 112		-5.3 (-	-7.52 (-13.44~-	-11.86 (-17.8~-
Model I	0(Ref)	11.62~0.64)	0.95)*	5.83)*
Model 1		-5.49 (-	-7.05 (-13.16~-	-11.95 (-18.08~-
baseline to baseline				
From 10 years before				
Model 2	U(Ref)	12.7~1.01)	3.82)*	3.29)*
Model 2	$0(\mathbf{P}_{af})$	-5.85 (-	-5.29 (-6.76~-	-6.1 (-8.91~-

Table S4 Association between uric acid and CVH scores.

е

¥7 ° 11		Univariate	Model	Multivariate Model	
Variable n –		β (95% CI)	P value	β (95% CI)	P value
Continuous, per 1 mg/dl	1257	-1.15 (-1.62~-0.67)	<0.001	-1.24 (-1.73~-0.74)	<0.001
Uric acid quartiles					
Quartile 1	288	0(Ref)		0(Ref)	
Quartile 2	322	0.28 (-1.63~2.2)	0.773	0.32 (-1.55~2.2)	0.736

^e CVH: cardiovascular health; Model 1 was a crude model; Model 2 was adjusted for age, sex, race, family PIR, educational level, marital status, drinking status. *: P < 0.05.

Quartile 3	304	-3.12 (-5.06~-1.17)	0.002	-3.36 (-5.3~-1.42)	0.001
Quartile 4	343	-3.95 (-5.84~-2.06)	<0.001	-4.2 (-6.14~-2.27)	< 0.001
f					

Table S5 Association between absolute weight change and uric acid

Variable		Univariate Model		Multivariate	Model
variable	n	β (95% CI)	P value	β (95% CI)	P value
From age 25 years to					
baseline					
Continuous, per 1 kg	1257	0.01 (0.01~0.02)	<0.001	0.02 (0.01~0.02)	< 0.001
Categories of Absolute					
Weight Change, kg					
$Loss \ge 2.5$	155	-0.01 (-0.34~0.32)	0.949	-0.1 (-0.4~0.2)	0.526
Change < 2.5(ref)	127	0(Ref)		0(Ref)	
Gain 2.5-< 10.0	260	0.19 (-0.11~0.48)	0.217	0.31 (0.04~0.58)	0.026
Gain 10-< 20.0	346	0.31 (0.03~0.6)	0.03	0.48 (0.22~0.74)	< 0.001
Gain ≥ 20.0	369	0.51 (0.23~0.8)	< 0.001	0.79 (0.53~1.05)	< 0.001

^f CVH: cardiovascular health; Model 1 was a crude model; Model 2 was adjusted for age, sex, race, family PIR, educational level, marital status, drinking status.

From age 25 years to

10 years before

baseline

Continuous, per 1 kg	1257	0.01 (0~0.02)	<0.001	0.01 (0.01~0.02)	<0.001
Categories of Absolute					
Weight Change, kg					
$Loss \ge 2.5$	78	-0.22 (-0.57~0.14)	0.234	-0.23 (-0.56~0.1)	0.178
Change < 2.5(ref)	252	0(Ref)		0(Ref)	
Gain 2.5-< 10.0	332	0.19 (-0.04~0.42)	0.103	0.25 (0.04~0.46)	0.022
Gain 10-< 20.0	316	0.29 (0.06~0.52)	0.013	0.3 (0.08~0.52)	0.007
Gain ≥ 20.0	279	0.48 (0.25~0.72)	<0.001	0.55 (0.33~0.77)	<0.001
From 10 years before					
baseline to baseline					
Continuous, per 1 kg	1257	0 (0~0.01)	0.282	0.01 (0~0.01)	0.001
Categories of Absolute					
Weight Change, kg					
$Loss \ge 2.5$	424	0.23 (0.02~0.44)	0.033	0.16 (-0.04~0.36)	0.108
Change < 2.5(ref)	277	0(Ref)		0(Ref)	
Gain 2.5-< 10.0	309	0.26 (0.03~0.49)	0.025	0.42 (0.21~0.63)	<0.001
Gain 10-< 20.0	159	0.2 (-0.07~0.48)	0.15	0.45 (0.19~0.71)	0.001

g

Table S6 Association between body mass index and uric acid

		Univariate	e Model	Multivariate Model	
Variable	n	β (95% CI) <i>P</i> value		β (95% CI)	P value
At age 25 years					
Continuous, per 1	1057	0.02 (0.01, 0.02)	-0.001	0.01 (0.0.02)	0.062
kg/m ²	1257	0.02 (0.01~0.03)	<0.001	0.01 (0~0.02)	0.062
BMI Categories					
Normal weight	828	0(Ref)		0(Ref)	
Underweight	71	-0.33 (-0.67~0)	0.054	-0.11 (-0.43~0.2)	0.484
Overweight	277	0.49 (0.3~0.68)	<0.001	0.23 (0.05~0.41)	0.014
Obesity	81	0.53 (0.21~0.85)	0.001	0.46 (0.16~0.76)	0.003
At 10 years before					
baseline					
Continuous, per 1	1055		0.001		0.001
kg/m ²	1257	0.04 (0.03~0.05)	<0.001	0.04 (0.02~0.05)	<0.001
BMI Categories					

^g Model 1 was a crude model; Model 2 was adjusted for age, sex, race, family PIR, educational level, marital status, drinking status.

Normal weight	360	0(Ref)		0(Ref)	
Underweight	15	-0.47 (-1.18~0.24)	0.197	-0.16 (-0.83~0.51)	0.642
Overweight	480	0.66 (0.47~0.84)	<0.001	0.49 (0.31~0.67)	< 0.001
Obesity	402	0.68 (0.48~0.87)	<0.001	0.55 (0.36~0.73)	< 0.001
At baseline					
Continuous, per 1	1257	0.05 (0.04, 0.06)	<0.001	0.06 (0.04, 0.07)	<0.001
kg/m ²	1237	0.03 (0.04~0.00)	<0.001	0.00 (0.04~0.07)	<0.001
BMI Categories					
Normal weight	360	0(Ref)		0(Ref)	
Underweight	15	-0.62 (-1.36~0.12)	0.1	-0.44 (-1.13~0.24)	0.206
Overweight	480	0.52 (0.32~0.72)	<0.001	0.47 (0.28~0.65)	< 0.001
Obesity	402	0.75 (0.55~0.96)	<0.001	0.81 (0.62~0.99)	< 0.001
h					

Table S7 Association between weight change patterns and uric acid.

	Stable	Weight loss, β	Weight gain, β	Stable obese, β
n	ion-obese	(95% CI)	(95% CI)	(95% CI)

From age 25 years to

baseline

^h Model 1 was a crude model; Model 2 was adjusted for age, sex, race, family PIR, educational level, marital status, drinking status.

Model 1	0(Ref)	0.53 (-	0.44 (0.27~0.6)*	0.6 (0.24~0.97)*				
	- ()	0.07~1.14)						
Madal 2	$\Omega(\mathbf{P}_{a}\mathbf{f})$	0.2(0.26, 0.86)	0.52	0.69				
Model 2	0(Rei)	0.5 (-0.20~0.80)	(0.36~0.67)*	(0.35~1.03)*				
From age 25 years to 10								
years before baseline								
N 111		0.1 (0.72, 0.04)	0.27	0.58				
Model I	0(Ref)	0.1 (-0.73~0.94)	(0.09~0.44)*	(0.23~0.92)*				
	0(D - D	0.24 (-	0.22	0.51				
Model 2	0(Kei)	0.54~1.01)	(0.05~0.39)*	(0.19~0.82)*				
From 10 years before								
baseline to baseline	baseline to baseline							
M 111		0.26 (-	0.48	0.48				
Model 1	0(Ref)	0.02~0.53)	(0.25~0.71)*	(0.29~0.68)*				
N 110		0.18 (-	0.66					
Model 2	U(Ref)	0.07~0.43)	(0.44~0.87)*	0.5 (0.32~0.68)*				

i

ⁱ Model 1 was a crude model; Model 2 was adjusted for age, sex, race, family PIR, educational level, marital status, drinking status. *: *P* < 0.05.



Fig. 1 Association between absolute weight change and CVH scores beta-coefficients. Solid and dashed lines represent the predicted value and 95% confidence intervals. The models were adjusted for age, sex, race, family PIR, educational level, marital status, drinking status. A: Absolute weight change from age 25 years to baseline, B: Absolute weight change from age 25 years to 10 years before baseline, C: Absolute weight change from 10 years before baseline to baseline



Fig.2 Depression score as a mediator of the relationship between BMI across three distinct life stages and CVH. Mediation analysis by the bootstrap test: adjusted for age, sex, race, family PIR, educational level, marital status, and drinking status. IE: indirect effect; DE: direct effect; CVD: cardiovascular diseases. *: P < 0.05



Fig. S1 The study' s flow diagram



Fig. S2 Uric acid as a mediator of the relationship between BMI at different life stages and CVH after adjusting for cardiovascular disease history. Mediation analysis by the bootstrap test: adjusted for age, sex, race, family PIR, educational level, marital status, drinking status and cardiovascular disease history. IE: indirect effect; DE: direct effect. *: P < 0.05



Fig. S3 Uric acid as a mediator of the relationship between BMI at different life stages and CVH in male. Mediation analysis by the bootstrap test: adjusted for age, race, family PIR, educational level, marital status, drinking status. IE: indirect effect; DE: direct effect. *: P < 0.05



Fig. S4 Uric acid as a mediator of the relationship between BMI at different life stages and CVH in female. Mediation analysis by the bootstrap test: adjusted for age, race, family PIR, educational level, marital status, drinking status. IE: indirect effect; DE: direct effect. *: P < 0.05



Fig. S5 Uric acid as a mediator of the relationship between BMI at different life stages and CVH younger than 65 years. Mediation analysis by the bootstrap test: adjusted for sex, race, family PIR, educational level, marital status, drinking status. IE: indirect effect; DE: direct effect. *: P < 0.05



Fig. S6. Uric acid as a mediator of the relationship between BMI at different life stages and CVH aged 65 years or older. Mediation analysis by the bootstrap test: adjusted for sex, race, family PIR, educational level, marital status, drinking status. IE: indirect effect; DE: direct effect. *: P < 0.05



	Total (n =	Low CVH	Moderate	High CVH	<i>P</i> value
Characteristic	1257)	(n = 119)	CVH (n =	(n = 157)	
			981)		
Sex ^a					0.502
Male	780 (62.1)	71 (59.7)	617 (62.9)	92 (58.6)	
Female	477 (37.9)	48 (40.3)	364 (37.1)	65 (41.4)	
Age , years ^a	64.4 ± 8.8	66.8 ± 9.8	64.4 ± 8.7	61.8 ± 7.2	< 0.001
Race ^a					0.004
Mexican American	117 (9.3)	13 (10.9)	96 (9.8)	8 (5.1)	
Non-Hispanic White	596 (47.4)	42 (35.3)	464 (47.3)	90 (57.3)	
Non-Hispanic Black	295 (23.5)	40 (33.6)	229 (23.3)	26 (16.6)	
Other race	249 (19.8)	24 (20.2)	192 (19.6)	33 (21)	
Family poverty-income ratio ^a					< 0.001
<1.3	287 (22.8)	41 (34.5)	228 (23.2)	18 (11.5)	
≥1.3	970 (77.2)	78 (65.5)	753 (76.8)	139 (88.5)	
Educational level ^a					< 0.001
Below high school	191 (15.2)	27 (22.7)	149 (15.2)	15 (9.6)	
High-school graduate	292 (23.2)	34 (28.6)	236 (24.1)	22 (14)	
College or above	774 (61.6)	58 (48.7)	596 (60.8)	120 (76.4)	
MS ^a					0.022
Married/living with partner	747 (59.4)	62 (52.1)	576 (58.7)	109 (69.4)	

Table 1 Baseline characteristics of participants classified by CVH category

Widowed/divorced/separated	425 (33.8)	44 (37)	340 (34.7)	41 (26.1)		
Never married	85 (6.8)	13 (10.9)	65 (6.6)	7 (4.5)		
Drinking status ^a					0.797	
No	856 (68.1)	78 (65.5)	672 (68.5)	106 (67.5)		
Yes	401 (31.9)	41 (34.5)	309 (31.5)	51 (32.5)		
Body mass index, kg/m ^{2 a}						
At age 25 years	23.7 ± 7.0	24.2 ± 4.0	23.9 ± 7.7	22.3 ± 3.3	0.023	
At 10 years before baseline	28.5 ± 6.2	31.5 ± 8.0	28.5 ± 5.9	26.0 ± 5.4	< 0.001	
At baseline	29.0 ± 5.9	33.2 ± 7.6	29.2 ± 5.6	25.1 ± 3.6	< 0.001	
Absolute weight change, kg ^b						
	12.4 (3.9,	23.6 (10.0,	13.1 (4.9,	4.7 (-0.5,	< 0.001	
From age 25 years to baseline	21.9)	34.0)	21.8)	11.4)		
From age 25 years to 10 years before	1.1 (-4.9,	5.5 (-5.5,	1.4 (-4.9,	-0.5 (-4.8,		
baseline	8.1)	16.2)	8.4)	3.8)	< 0.001	
From 10 years before baseline to	9.1 (2.3,	13.6 (6.8,	9.1 (2.3,	4.5 (0.9,		
baseline	18.1)	26.8)	18.1)	12.7)	< 0.001	
depression score ^a	5.7 ± 1.4	5.9 ± 1.4	5.7 ± 1.4	5.2 ± 1.4	< 0.001	

а

^a Continuous variables are presented as mean \pm SD; categorical variables are presented as N(%).

^a CVH cardiovascular health.

^b Those characteristics were presented as median (IQR).

Variable	n	Univariate	Model	Multivariate	Multivariate Model	
Variable	11	β (95% CI)	P value	β (95% CI)	P value	
From age 25 years to						
baseline						
Continuous, per 1 kg	1257	-0.24 (-0.28~-0.2)	< 0.001	-0.24 (-0.28~-0.2)	< 0.001	
Categories of Absolute						
Weight Change, kg						
$Loss \ge 2.5$	155	-3.58 (-6.27~-0.9)	0.009	-2.7 (-5.29~-0.1)	0.042	
Change < 2.5(ref)	127	0(Ref)		0(Ref)		
Gain 2.5-< 10.0	260	-1.39 (-3.81~1.04)	0.263	-1.61 (-3.96~0.74)	0.179	
Gain 10-< 20.0	346	-4.33 (-6.65~-2)	<0.001	-4.53 (-6.79~-2.28)	<0.001	
Gain ≥ 20.0	369	-11.6 (-13.91~-9.3)	<0.001	-11.27 (-13.53~-9)	< 0.001	
From age 25 years to						
10 years before						
baseline						
Continuous, per 1 kg	1257	-0.16 (-0.21~-0.11)	< 0.001	-0.17 (-0.22~-0.13)	< 0.001	
Categories of Absolute						
Weight Change, kg						
$Loss \ge 2.5$	78	0.78 (-2.27~3.83)	0.616	-0.09 (-3.02~2.83)	0.95	
Change < 2.5(ref)	252	0(Ref)		0(Ref)		

Table 2 Association between absolute weight change and CVH scores.

Gain 2.5-< 10.0	332	-0.44 (-2.4~1.53)	0.662	-1.54 (-3.44~0.36)	0.111
Gain 10-< 20.0	316	-2.2 (-4.19~-0.22)	0.03	-3.54 (-5.47~-1.61)	< 0.001
$Gain \ge 20.0$	279	-5.74 (-7.79~-3.7)	< 0.001	-6.78 (-8.75~-4.8)	< 0.001
From 10 years before					
baseline to baseline					
Continuous, per 1 kg	1257	-0.14 (-0.19~-0.09)	<0.001	-0.13 (-0.17~-0.08)	< 0.001
Categories of Absolute					
Weight Change, kg					
$Loss \ge 2.5$	424	-3.73 (-5.5~-1.96)	<0.001	-2.97 (-4.71~-1.24)	0.001
Change < 2.5(ref)	277	0(Ref)		0(Ref)	
Gain 2.5-< 10.0	309	-2.99 (-4.89~-1.1)	0.002	-2.5 (-4.37~-0.63)	0.009
C.:	150	0.09 (11.25 (0)	-0.001	-7.96	-0.001
Gain 10-< 20.0	159	-9.08 (-11.30~-0.8)	<0.001	(-10.24~-5.68)	<0.001
	00	-12.82	0.001	-11.09	0.001
Gain ≥ 20.0	88	(-15.63~-10.02)	<0.001	(-13.89~-8.29)	<0.001

educational level, marital status, drinking status.

а

^a CVH: cardiovascular health; Model 1 was a crude model; Model 2 was adjusted for age, sex, race, family PIR,



Fig. 1 Association between absolute weight change and CVH scores beta-coefficients. Solid and dashed lines represent the predicted value and 95% confidence intervals. The models were adjusted for age, sex, race, family PIR, educational level, marital status, drinking status. A: Absolute weight change from age 25 years to baseline, B: Absolute weight change from age 25 years to 10 years before baseline, C: Absolute weight change from 10 years before baseline to baseline



Fig.2 Uric acid as a mediator of the relationship between BMI across three distinct life stages and CVH. Mediation analysis by the bootstrap test: adjusted for age, sex, race, family PIR, educational level, marital status, and drinking status. IE: indirect effect; DE: direct effect; CVD: cardiovascular diseases. *: P < 0.05



Fig. S1 The study' s flow diagram

Figure S1



Fig. S2 Uric acid as a mediator of the relationship between BMI at different life stages and CVH after adjusting for cardiovascular disease history. Mediation analysis by the bootstrap test: adjusted for age, sex, race, family PIR, educational level, marital status, drinking status and cardiovascular disease history. IE: indirect effect; DE: direct effect. *: P < 0.05



Fig. S3 Uric acid as a mediator of the relationship between BMI at different life stages and CVH in male. Mediation analysis by the bootstrap test: adjusted for age, race, family PIR, educational level, marital status, drinking status. IE: indirect effect; DE: direct effect. *: P < 0.05



Fig. S4 Uric acid as a mediator of the relationship between BMI at different life stages and CVH in female. Mediation analysis by the bootstrap test: adjusted for age, race, family PIR, educational level, marital status, drinking status. IE: indirect effect; DE: direct effect. *: P < 0.05



Fig. S5 Uric acid as a mediator of the relationship between BMI at different life stages and CVH younger than 65 years. Mediation analysis by the bootstrap test: adjusted for sex, race, family PIR, educational level, marital status, drinking status. IE: indirect effect; DE: direct effect. *: P < 0.05



Fig. S6. Uric acid as a mediator of the relationship between BMI at different life stages and CVH aged 65 years or older. Mediation analysis by the bootstrap test: adjusted for sex, race, family PIR, educational level, marital status, drinking status. IE: indirect effect; DE: direct effect. *: P < 0.05